Cholesterol Efflux and Atheroprotective Effects Video Interview Activity

Title:

Cholesterol Efflux and Atheroprotective Effects Video Interview Activity

Topic: Cardiology
Relevant Terms: Cholesterol Efflux
Primary Audience: Cardiologists and other physicians, clinicians and health care providers involved in the treatment of patients with lipid disorders and cardiovascular disease.
Launch Date: 04-Oct-12
Credits: 1.75 AMA PRA Category 1 Credits
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Review the historical concept of high-density lipoprotein (HDL)-mediated reverse cholesterol transport
  2. Discuss the anti-atherosclerotic role of HDL particles
  3. Describe molecular systems involved in cholesterol efflux
  4. Review the use of animal models and discuss the role of non-invasive imaging in revealing mechanisms of cholesterol efflux

    Faculty

    H. Bryan Brewer, Jr., MD, FNLA
    Director, Washington Cardiovascular Associates
    Senior Research Consultant
    Lipoprotein and Atherosclerosis Research
    MedStar Research Institute
    Washington Hospital Center
    Washington, DC
    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Director, Cardiometabolic Disorders
    Mount Sinai Heart
    Professor of Medicine
    Mount Sinai School of Medicine
    New York, New York
    W. Sean Davidson, PhD
    Professor and Director
    Center for Lipid and Arteriosclerosis Science
    University of Cincinnati
    Cincinnati, Ohio
    Zahi A. Fayad, PhD
    Professor of Radiology and Medicine (Cardiology)
    Director, Translational and Molecular Imaging Institute 
    Mount Sinai School of Medicine
    New York, New York
    Raniel J. Rader, MD
    Professor of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania
    Alan R. Tall, MD
    Tilden Weger Bieler Professor of Medicine
    Professor of Physiology and Cellular Biophysics
    Director, Division of Molecular Medicine
    Columbia University Medical Center
    New York, New York
    Welcome! Please review the following CME information for this activity and click "Proceed to Course" to enter the activity.

    Release Date: October 2012
    Expiration Date: October 2013
    Estimated time to complete activity: 1.75 hours
    System requirements: any modern web browser is required to view the video content for this activity. High-speed internet access is also recommended. This activity is supported on iPad and Android tablet devices. This activity will work on iPhones and Android phones; however, the media is not optimized for these devices.

    Target Audience
    This activity has been designed to meet the educational needs of cardiologists and other physicians, clinicians, and health care providers involved in the treatment of patients with lipid disorders and cardiovascular disease.

    Program Overview
    In this activity, expert faculty will present their perspectives and provide insight into the emerging science and the potential clinical application of important research being conducted in the area of cholesterol efflux and atherogenic protection. During the discussions, experts will review the scientific data related to the current understanding of high-density lipoprotein (HDL)-mediated reverse cholesterol transport and the anti-atherosclerotic role of HDL particles. In addition, the potential role of imaging to identify high-risk or vulnerable plaques and the burden of atherosclerotic disease also are discussed.

    Program Agenda
    The Cholesterol Efflux and Atheroprotective Effects Video Interview Activity is a part of the Academy for the Advancement of HDL Science continuing educational series.
     
    This activity consists of a video introduction on the Reverse Cholesterol Transport Evolution, a brief activity overview, and 5 video interviews in which experts in the cardiovascular field explore the emerging science and potential clinical application of important research being conducted in the area of cholesterol efflux and atherogenic protection. The following topics are discussed:
     
    • Introduction: Evolution of the Reverse Cholesterol Transport Concept
    H. Bryan Brewer, Jr., MD
     
    • Activity Overview: Cholesterol Efflux Chapter Summary
    H. Bryan Brewer, Jr., MD
     
    • HDL Particle Structure-Activity Relationships: Importance in Cholesterol Efflux Pathways
    W. Sean Davidson, PhD, and Robert S. Rosenson, MD
     
    • Nuclear Receptors Mediating RCT: ABCA1 and ABCG1 in the Regulation of Cellular Cholesterol Efflux, Cell Proliferation, and Atherosclerosis
    Alan R. Tall, MD, and Robert S. Rosenson, MD

    • Contribution of Pathways to Cell Cholesterol Efflux
    Daniel J. Rader, MD, and H. Bryan Brewer, Jr., MD

    • ApoA-I Mimetics
    H. Bryan Brewer, Jr., MD and Robert S. Rosenson, MD
     
    • Vascular Imaging of Atheroma in the Evaluation of HDL-Modifying Therapies
    Zahi A. Fayad, PhD, and H. Bryan Brewer, Jr., MD
     
    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications (CMC). MER is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    MER designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    To contact MER, please call 303-798-9682.
     
    Disclosure of Conflicts of Interest
    MER insures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.
     
    The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:
    Name of Faculty
    Reported Financial Relationship
    H. Bryan Brewer, Jr., MD
    Consulting fees from and speakers' bureau participant with AstraZeneca, Lilly, Merck, Pfizer, and Roche; ownership interest/shareholder in HDL Therapeutics and The Medicines Company; and royalty/patent holder with HDL Therapeutics
    W. Sean Davidson, PhD
    Grants/research support from National Institutes of Health and Roche Pharmaceuticals and speakers' bureau participant with Merck
    Zahi A. Fayad, PhD
    Grants/research support from Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Roche Pharmaceuticals, and VBL Therapeutics and consulting fees from Roche Pharmaceuticals
    Daniel J. Rader, MD
    Consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo; Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Novartis, Omthera, Pfizer, Regeneron, and Sanofi-Aventis and stock/shareholder in Aegerion Pharmaceuticals and Vascular Strategies
    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Grants/research support from Amgen, Genentech, Roche, and Sanofi Aventis; consulting fees from Abbott Laboratories, Amgen, Genentech, LipoScience, Roche, and Sanofi Aventis; and ownership interest/shareholder in LipoScience
    Alan R. Tall, MD
    Grants/research support from CSL; consulting fees from Amgen, CSL, MRL, Roche, and Novartis; speakers' bureau participant with MRL; ownership/shareholder in Arisaph; and salary from National Institutes of Health

     
    The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

    Name of Content Manager
    Reported Financial Relationship
    Jennifer Frederick, PharmD, BCPS
    No financial relationships to disclose
    Amanda Kershaw, PharmD
    No financial relationships to disclose
     
    Method of Participation
    There are no fees for participating in and receiving CME credit for this activity. During the period October 2012 through October 2013, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest, and 4) complete the evaluation form.
     
    A statement of credit will be issued only upon electronic submission of a completed activity evaluation form and a completed posttest with a score of 70% or better. Statements of credit should be printed online upon completion of the activity via the NLA website.
     
    Media
    Internet
     
    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of MER, CMC, or Genentech. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MER, CMC, and Genentech. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
     
    Medical Education Resources Privacy Policy
    MER and CMC maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
     
    The only information MER obtains is information supplied voluntarily by the visitor. We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property. We use the information to grade your posttest and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.
     
    For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
     
    We may use the information to invite you to participate in other CME activities that we may offer.
     
    On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity in order to document the first level of outcomes-based evaluation in CME (eg, who attended, which medical specialties/practices were represented, how this compares with the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will request in writing that the supporter not contact you directly for any purpose.
     
    MER is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us at info@cmepartner.org.
     


    This activity is supported by an educational grant from Genentech